Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $66.67 Average Price Target from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $66.6667.

Several equities analysts recently commented on RVPH shares. Maxim Group reissued a “hold” rating on shares of Reviva Pharmaceuticals in a report on Wednesday. Chardan Capital reissued a “buy” rating and issued a $40.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the second quarter valued at $31,000. Lido Advisors LLC acquired a new position in Reviva Pharmaceuticals in the third quarter valued at $37,000. NewEdge Advisors LLC acquired a new position in Reviva Pharmaceuticals in the first quarter valued at $58,000. State Street Corp boosted its stake in Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after acquiring an additional 256,500 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $0.79 on Monday. The firm has a market capitalization of $10.12 million, a PE ratio of -0.09 and a beta of 0.64. The business’s fifty day moving average price is $3.35 and its 200 day moving average price is $7.48. Reviva Pharmaceuticals has a 12 month low of $0.59 and a 12 month high of $23.20.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.